Although the first patent for Wellbutrin XL doesn't expire until 2018, a United States District Court ruled that generic Wellbutrin XL could be made. The FDA has assigned an "AB" rating to the generic version, which means that it is considered equivalent to the brand-name version, although it may have different inactive ingredients.
An Overview of Generic Wellbutrin XL
Wellbutrin XL® (bupropion XL) is a prescription medicine used for the treatment of depression (also known as major depression or clinical depression). It is also used to prevent seasonal affective disorder (SAD).
Wellbutrin XL was first manufactured by GlaxoSmithKline. The first patent expires in 2018. However, it was questionable if this patent could prevent generic Wellbutrin XL from being made, and there have been several lawsuits surrounding this issue. In 2006, a U.S. District Court ruled in favor of a generic manufacturer, essentially deciding that generic Wellbutrin XL could be made.
Names and Strengths of the Generic Versions
Generic Wellbutrin XL tablets are available in the following strengths:
Generic manufacturers may choose to use a standard generic name or create their own name. One maker of generic Wellbutrin XL has chosen to create its own name: Budeprion XL®. Although initially available in both strengths, the 300-mg strength of Budeprion XL was withdrawn from the market in 2012 after it was shown not to be equivalent to Wellbutrin XL (it is not absorbed as well). Other versions of the 300-mg generic are still available.
Who Makes Generic Wellbutrin XL?
Various manufacturers make generic versions of Wellbutrin XL, such as:
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Wellbutrin XL [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2013 March.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA Update: Budeprion XL 300 mg not therapeutically equivalent to Wellbutrin XL 300 mg (10/3/2012). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm322161.htm. Accessed October 22, 2012.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed February 15, 2007.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click